agar 7h10 medium (MiddleBrook Pharmaceuticals)
Structured Review

Agar 7h10 Medium, supplied by MiddleBrook Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/agar 7h10 medium/product/MiddleBrook Pharmaceuticals
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity"
Article Title: Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
Journal: Human Vaccines & Immunotherapeutics
doi: 10.1080/21645515.2017.1316911

Figure Legend Snippet: Phenotypic characterization of BCG.HIVA 2auxo.int strain. We assessed the phenotype of lysine auxotrophy, lysine complementation and kanamycin resistance of BCG.HIVA 2auxo.int strain (A) BCG lysine auxotroph strain plated on non-lysine supplemented 7H10; (B) BCG lysine auxotroph strain plated on lysine supplemented 7H10; (C) BCG.HIVA 2auxo.int plated on 7H10 without lysine and kanamycin supplementation; (D) BCG.HIVA 2auxo.int plated on 7H10 without lysine supplementation and with kanamycin.
Techniques Used:
2) Product Images from "Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity"
Article Title: Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
Journal: Human Vaccines & Immunotherapeutics
doi: 10.1080/21645515.2017.1316911

Figure Legend Snippet: Phenotypic characterization of BCG.HIVA 2auxo.int strain. We assessed the phenotype of lysine auxotrophy, lysine complementation and kanamycin resistance of BCG.HIVA 2auxo.int strain (A) BCG lysine auxotroph strain plated on non-lysine supplemented 7H10; (B) BCG lysine auxotroph strain plated on lysine supplemented 7H10; (C) BCG.HIVA 2auxo.int plated on 7H10 without lysine and kanamycin supplementation; (D) BCG.HIVA 2auxo.int plated on 7H10 without lysine supplementation and with kanamycin.
Techniques Used:
3) Product Images from "Pre-Clinical Development of BCG.HIVACAT, an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG"
Article Title: Pre-Clinical Development of BCG.HIVACAT, an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG
Journal: PLoS ONE
doi: 10.1371/journal.pone.0042559

Figure Legend Snippet: Phenotypic characterization of the BCG.HIVA CAT . We assessed the phenotype of lysine auxotrophy, lysine complementation and kanamycin resistance of BCG.HIVA CAT strain. ( A ) BCG lysine auxotroph strain plated on non-lysine supplemented 7H10; ( B ) BCG lysine auxotroph strain plated on lysine supplemented 7H10; ( C ) BCG.HIVA CAT plated on 7H10 without lysine and kanamycin supplementation; ( D ) BCG.HIVA CAT plated on 7H10 without lysine supplementation and with kanamycin.
Techniques Used:
4) Product Images from "MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice"
Article Title: MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice
Journal: Molecular Therapy. Methods & Clinical Development
doi: 10.1016/j.omtm.2019.01.014

Figure Legend Snippet: Construction of MTBVAC.HIVA 2auxo (A) The HIVA gene was fused to the region encoding the 19-kDa lipoprotein signal sequence of the episomal p2auxo.Ø E. coli -mycobacterial shuttle plasmid to obtain p2auxo.HIVA plasmid. The BALB/c mouse T cell and Mab-Pk epitopes used in this study are depicted. P α-Ag ( M. tuberculosis α-antigen promoter), PHSP60 (heat shock protein 60 gene promoter), and glyA - and lysA -complementing genes are used as markers for selection and maintenance in E. coli M15Δ Gly and MTBVACΔ lys , respectively. (B) Phenotypic characterization of the lysine auxotrophy and plasmid complementation of MTBVACΔ lys and MTBVAC.HIVA 2auxo (MTBVACΔ lys plated on lysine-supplemented 7H10, left; MTBVACΔ lys plated on non-lysine-supplemented 7H10, center; and MTBVAC.HIVA 2auxo plated on non-lysine-supplemented 7H10, right). (C) Western blot of MTBVACHIVA 2auxo lysates. Lanes 1 and 2, MTBVAC.Ø 2auxo clones 1 and 2; lanes 3 and 5, MTBVAC.HIVA 2auxo ; lane 6, BCG wild-type lysate (negative control). HIVA immunogen was detected using the anti-Pk monoclonal antibodies (mAbs) followed by horseradish peroxidase-protein A and enhanced chemiluminescence detection.
Techniques Used: Sequencing, Plasmid Preparation, Selection, Western Blot, Clone Assay, Negative Control

Figure Legend Snippet: Genetic Stability of p2auxo.HIVA Plasmid DNA (A) In vitro . Serial passages of the working vaccine stock (WVS) were performed weekly (+1 to +6), and HIVA PCRs were used to check stability of the plasmid DNA. Lane 1, WVS MTBVAC.HIVA 2auxo ; lanes 2–4, passages +4, +5, and +6 WVS MTBVAC.HIVA 2auxo ; lane 5, H 2 0 (negative control); lane 6, positive control; lane 7, molecular weight marker. (B) In vivo . Spleens from SCID mice inoculated with 10 6 CFU MTBVAC.HIVA 2auxo and used for safety experiments were harvested and plated on complete 7H10 supplemented with Lys and Km. The presence of p2auxo.HIVA plasmid in the colonies from these mice was analyzed by specific PCR using the pairs of primers to detect HIVA (19kDss-fw/HIVA-rv). Each number represents one colony and numbers with # symbol indicate colonies from the same animal. Minus and plus symbols indicate negative and positive controls of PCR, respectively. Plasmid maintained in vivo was calculated as the percent of positive colonies with respect to total colonies analyzed.
Techniques Used: Plasmid Preparation, In Vitro, Negative Control, Positive Control, Molecular Weight, Marker, In Vivo, Mouse Assay, Polymerase Chain Reaction

Figure Legend Snippet: Construction and Characterization of MTBVACΔ lys Strain (A) lysA gene (gray arrow) from MTBVAC was inactivated using homologous recombination techniques by introducing a kanamycin resistance cassette (gray rectangle), flanked by two resolvase sites (white arrowheads) in order to allow the release of the resistance cassette. The inactivated phoP and fadD2 6 genes in the MTBVAC parental strain are also illustrated. (B) Genotypic characterization of the lysA gene inactivation by the kanamycin cassette (km) insertion, primers used, and expected sizes of the PCR products are indicated. MTBVAC sample was used in lanes 3, 5, and 7 and MTBVACΔ lys samples in lanes 4, 6, and 8. Lane 1, molecular weight marker; lane 2, negative control; lanes 3 and 4, PCR product of the lysA gene using Lys-fw and Lys-rv primers; lanes 5 and 6, PCR of the 5′ insertion point of km expression cassette using Lys-fw and km-OUT-rv primers; and lanes 7 and 8, PCR of the 3′ insertion point of km expression cassette using km-OUT-fw and Lys-rv primers. Genes are represented as gray arrows; gray rectangles illustrate antibiotic resistance markers and white arrowheads depict resolvase recognition sequences or res sites. (C) Phenotypic lysine auxotrophic verification by plating MTBVACΔ lys strain in 7H10-ADC with and without lysine supplementation.
Techniques Used: Homologous Recombination, Polymerase Chain Reaction, Molecular Weight, Marker, Negative Control, Expressing
5) Product Images from "Pre-Clinical Development of BCG.HIVACAT, an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG"
Article Title: Pre-Clinical Development of BCG.HIVACAT, an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG
Journal: PLoS ONE
doi: 10.1371/journal.pone.0042559

Figure Legend Snippet: Phenotypic characterization of the BCG.HIVA CAT . We assessed the phenotype of lysine auxotrophy, lysine complementation and kanamycin resistance of BCG.HIVA CAT strain. ( A ) BCG lysine auxotroph strain plated on non-lysine supplemented 7H10; ( B ) BCG lysine auxotroph strain plated on lysine supplemented 7H10; ( C ) BCG.HIVA CAT plated on 7H10 without lysine and kanamycin supplementation; ( D ) BCG.HIVA CAT plated on 7H10 without lysine supplementation and with kanamycin.
Techniques Used: